Mounjaro vs. Zepbound: Same Drug, Different FDA Approval

Mounjaro and Zepbound are the same molecule from the same manufacturer, and the confusion between them runs the same direction as Ozempic and Wegovy — except the details actually differ. Here is the specific comparison, including the one thing that is identical between them, which is not the case for semaglutide's two brands.

Both are tirzepatide, on two separate approvals

Mounjaro was approved first, in May 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes¹. Zepbound followed in November 2023, approved specifically for chronic weight management — to reduce excess body weight and maintain the reduction, combined with a reduced-calorie diet and increased physical activity, in adults with obesity or overweight plus a weight-related condition². The FDA later expanded Zepbound's approved use again, adding treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, on the strength of the SURMOUNT-OSA trial, which found tirzepatide reduced the apnea-hypopnea index by an estimated 20.0 events per hour more than placebo at 52 weeks³. Mounjaro's label carries no such sleep-apnea indication — a real difference beyond just the name.

The dose ceiling, unlike Ozempic and Wegovy, is identical

This is the detail worth knowing precisely because it cuts against the semaglutide pattern. Ozempic and Wegovy have different maximum approved doses (2 mg versus 2.4 mg). Mounjaro and Zepbound do not: both share the same recommended maintenance dosages — 5 mg, 10 mg, or 15 mg once weekly — and the same maximum dosage of 15 mg subcutaneously once weekly¹². The pivotal weight-loss trial, SURMOUNT-1, tested those same three doses and reported mean weight reductions of about −15.0%, −19.5%, and −20.9% at 5 mg, 10 mg, and 15 mg respectively over 72 weeks⁴. So a patient titrated to Mounjaro's top dose for diabetes is, dose-for-dose, on the same tirzepatide dose Zepbound's own trial evidence is built on — the two brands diverge on approved use and label, not on how high the syringe goes.

Why the approval difference still matters

Even with matching doses, the separate approvals carry real downstream consequences. Insurance coverage typically follows the labeled indication: a plan may cover Mounjaro for a documented type 2 diabetes diagnosis while excluding Zepbound when the only indication on the chart is weight management — the mechanics of that split are covered in does insurance cover GLP-1 weight-loss drugs? Prescribing Mounjaro specifically for weight loss in a patient without diabetes is off-label use; it's legal for a licensed prescriber but is a different footing than prescribing Zepbound on-label for the same goal, and a provider should be willing to tell you plainly which one your prescription is.

Where compounded "tirzepatide" fits in

Neither brand is what most compounded telehealth providers dispense. Compounded tirzepatide is a separate pharmacy-prepared product, and whether it's lawful to sell at scale right now depends on the mechanism explained in why compounded GLP-1's legality hinges on the FDA shortage list — a provider invoking "Mounjaro" or "Zepbound" by name to describe a compounded product is making a molecule-level comparison, not a claim that you're receiving either FDA-approved product.

So which name should you ask for?

Ask about the indication, not the brand. If you have diagnosed type 2 diabetes, Mounjaro's approval and your insurer's formulary logic are built around that diagnosis. If your goal is weight management, or you have obesity with moderate-to-severe sleep apnea, Zepbound is the on-label product with trial evidence built for exactly those uses. Since the dose ceiling is identical either way, the real decision is about diagnosis, coverage, and the provider's oversight — covered in full in our six-point checklist — not about which brand climbs higher on the syringe.

The honest bottom line

Mounjaro and Zepbound are the same molecule at the same maximum dose, approved by the FDA for different reasons — and unlike Ozempic and Wegovy, the dose ceiling isn't the thing that separates them; the indication, the insurance logic behind it, and (for Zepbound) the added sleep-apnea approval are. Compare graded providers' tirzepatide access and pricing in our reviews and comparisons A licensed clinician should be the one matching the product to your diagnosis.